Structural Characterization of the Interaction of γ-Secretase with GSM-1 Modulator
- 2 May 2026
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (10) , 1870-1878
Abstract
γ-Secretase (GS) is a key therapeutic target in Alzheimer’s disease because it catalyzes amyloid-β production. To reduce toxic amyloid-β species, several γ-secretase modulators (GSMs) have been developed. Among these, GSM-1, a piperidine carboxylic acid-based modulator, has shown potent activity in preclinical studies; however, its binding site and molecular mechanism remain unclear. Here, a molecular dynamics protocol inspired by the Wrap-‘N’-Shake approach was used to investigate how the axial and equatorial conformations of the piperidine nitrogen in GSM-1 interact with GS’s presenilin subunit. Both conformations formed stable interactions with presenilin TM1 and TM5. The carboxylate group established persistent interactions with R220 in TM5, while the trifluoromethylphenyl group engaged residues K76, K80, V87, and L91 in TM1. These findings provide the first model of GSM-1 engagement with GS, identify the key GSM-1 chemical groups involved in recognition, and establish a mechanistic foundation for the rational design of next-generation GSM analogs.Keywords
Funding Information
- Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (PAPIIT - IN208025)
- Universidad Nacional Autónoma de México (LANCAD-UNAM-DGTIC-306)
- Universidad Nacional Autónoma de México (PAIP - 5000-9155)
This publication has 46 references indexed in Scilit:
- 2024 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2024
- Alzheimer's disease drug development pipeline: 2022Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022
- Current druggable targets for therapeutic control of Alzheimer's diseaseContemporary Clinical Trials, 2021
- Structural basis of γ-secretase inhibition and modulation by small molecule drugsCell, 2021
- γ-Secretase Modulators as Aβ42-Lowering Pharmacological Agents to Treat Alzheimer’s Disease2017
- CHARMM‐GUI 10 years for biomolecular modeling and simulationJournal of Computational Chemistry, 2016
- Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer’s diseaseBioorganic & Medicinal Chemistry Letters, 2013
- Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s DiseaseCellular and Molecular Neurobiology, 2011
- Piperidine-derived γ-secretase modulatorsBioorganic & Medicinal Chemistry Letters, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009